BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 12, 2020
Product Development

Lining up allogeneic CAR Ts at ASH: Data Byte

Promising efficacy data from China’s Bioheng are among the allogeneic CAR T cell updates at ASH this year.  The past year has seen a growing number of clinical readouts for off-the-shelf allogeneic...
BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

As it awaits more clarity on a path forward for autoimmune candidate filgotinib, Gilead is leaning on its recent spate of cancer deals, most notably with ADC developer Immunomedics, for near-term growth.  Filgotinib, the centerpiece of...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...
BioCentury | Oct 13, 2020

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

Immuneel, a Bangalore start-up dedicated to making cancer cell therapies available in India at prices far below those charged in developed countries, announced Tuesday its first step to bring CAR T treatments to the subcontinent. Immuneel Therapeutics...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the...
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago scientists reported in Science Advances that NF-κB modulator SN50 could enable the use of adjuvants to amplify adaptive immune response by...
BioCentury | Aug 20, 2020

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx and Harmony posting double-digit gains Wednesday after pricing upsized NASDAQ IPOs late Tuesday, and JW and Harbour lining up...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Apr 23, 2020

FDA’s options for staying on track with PDUFA timelines during COVID-19

The COVID-19 pandemic is severely limiting FDA’s ability to conduct in-person pre-approval site inspections, putting the agency’s ability to meet its regulatory timelines at risk. To avoid delays, companies need to prepare to provide all...
Items per page:
1 - 10 of 116